Insights

Innovation Leadership NIOX Group plc is a recognized leader in the FeNO testing industry, with a strong reputation for developing reliable, non-invasive asthma diagnostic tools like the NIOX VERO®. This positions the company as a key vendor for healthcare providers seeking advanced respiratory diagnostic solutions.

Strategic Partnerships Recent collaborations with Vitalograph Inc and the AHSN Network highlight NIOX's active efforts to expand its market reach and enhance testing accessibility, creating opportunities for joint ventures and increased product distribution channels.

Growing Market Focus With the global emphasis on improving asthma management, NIOX’s specialized medical devices are positioned to benefit from rising demand for accurate, bedside diagnostic tools in clinics, hospitals, and primary care settings.

Product Expansion Potential NIOX has demonstrated capacity for launching related respiratory treatments, such as Duaklir Pressair for COPD, indicating potential avenues to cross-sell or bundle additional respiratory management solutions to existing healthcare clients.

Financial Growth Opportunities While current revenues are within the $1M to $10M range, targeted sales initiatives focusing on expanding institutional adoption and leveraging existing partnerships could significantly scale revenue streams in the respiratory diagnostics space.

Similar companies to FeNO by NIOX® USA

FeNO by NIOX® USA Tech Stack

FeNO by NIOX® USA uses 8 technology products and services including LinkedIn Ads, BootstrapCDN, Preact, and more. Explore FeNO by NIOX® USA's tech stack below.

  • LinkedIn Ads
    Advertising
  • BootstrapCDN
    Content Delivery Network
  • Preact
    Javascript Libraries
  • jQuery Migrate
    Javascript Libraries
  • FancyBox
    Javascript Libraries
  • UNIX
    Operating Systems
  • reCAPTCHA
    Security
  • Cloudflare Bot Management
    Security

FeNO by NIOX® USA's Email Address Formats

FeNO by NIOX® USA uses at least 2 format(s):
FeNO by NIOX® USA Email FormatsExamplePercentage
First.Last@circassia.comJohn.Doe@circassia.com
85%
FirstLast@circassia.comJohnDoe@circassia.com
4%
First.Middle@circassia.comJohn.Michael@circassia.com
1%
First-Last@circassia.comJohn-Doe@circassia.com
2%
FiLast@circassia.comJoDoe@circassia.com
1%
First_Last@circassia.comJohn_Doe@circassia.com
1%
Last.First@circassia.comDoe.John@circassia.com
1%
LastFir@circassia.comDoeJoh@circassia.com
1%
FirstLa@circassia.comJohnDo@circassia.com
1%
F-Last@circassia.comJ-Doe@circassia.com
1%
Last.F@circassia.comDoe.J@circassia.com
1%
First@circassia.comJohn@circassia.com
1%
First.Last@niox.comJohn.Doe@niox.com
71%
FirLast@niox.comJohDoe@niox.com
17%
FiLast@niox.comJoDoe@niox.com
6%
FLast@niox.comJDoe@niox.com
6%

Frequently Asked Questions

Where is FeNO by NIOX® USA's headquarters located?

Minus sign iconPlus sign icon
FeNO by NIOX® USA's main headquarters is located at 1100 Perimeter Park Drive Suite 114 Morrisville, North Carolina 27560 United States. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is FeNO by NIOX® USA's official website and social media links?

Minus sign iconPlus sign icon
FeNO by NIOX® USA's official website is niox.com and has social profiles on LinkedIn.

What is FeNO by NIOX® USA's NAICS code?

Minus sign iconPlus sign icon
FeNO by NIOX® USA's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does FeNO by NIOX® USA have currently?

Minus sign iconPlus sign icon
As of March 2026, FeNO by NIOX® USA has approximately 10 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: S. H.Chief Operating Officer: J. E.Chief Commercial Officer: L. S.. Explore FeNO by NIOX® USA's employee directory with LeadIQ.

What industry does FeNO by NIOX® USA belong to?

Minus sign iconPlus sign icon
FeNO by NIOX® USA operates in the Medical Equipment Manufacturing industry.

What technology does FeNO by NIOX® USA use?

Minus sign iconPlus sign icon
FeNO by NIOX® USA's tech stack includes LinkedIn AdsBootstrapCDNPreactjQuery MigrateFancyBoxUNIXreCAPTCHACloudflare Bot Management.

What is FeNO by NIOX® USA's email format?

Minus sign iconPlus sign icon
FeNO by NIOX® USA's email format typically follows the pattern of First.Last@circassia.com. Find more FeNO by NIOX® USA email formats with LeadIQ.

When was FeNO by NIOX® USA founded?

Minus sign iconPlus sign icon
FeNO by NIOX® USA was founded in 2006.

FeNO by NIOX® USA

Medical Equipment ManufacturingNorth Carolina, United States2-10 Employees

NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO®, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma.

NIOX VERO® provides accurate and reliable results, allowing healthcare
professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, and can be used in a variety of settings, including clinics, hospitals, and primary care settings.

The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX® is also committed to offering additional training and support for healthcare professionals.

Overall, NIOX Group plc is the global leader in FeNO testing, with a strong
reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO®, healthcare professionals have a reliable and non-invasive tool to help them better diagnose and manage asthma.

References:
1. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218.
2. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1
3. Busse WW et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173.
4. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633.
5. NIOX®. Data on File; MKT-DOF-007.

Section iconCompany Overview

Headquarters
1100 Perimeter Park Drive Suite 114 Morrisville, North Carolina 27560 United States
Website
niox.com
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2006
Employees
2-10

Section iconFunding & Financials

  • $1M$10M

    FeNO by NIOX® USA's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    FeNO by NIOX® USA's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.